Drug Database
Back to search

Netherlands· NL-e92052405410

Lantus 100 eenheden/ml oplossing voor injectie in een injectieflacon

A insulin glargine product containing insuline glargine, registered in Netherlands by Sanofi-Aventis Deutschland GmbH. The same ATC class is registered in 13 of our 19 countries.

ATC A10AE04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLantus 100 eenheden/ml oplossing voor…ATCA10AE04REGISTER NO.NL-e92052405410PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insuline glargineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin glargine is registered in 13 of 19 countries.

Countries holding a registration under ATC A10AE04 (insulin glargine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search insulin glargine products by name

Insulin glargine · ATC A10AE04

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
INSULINE GLARGINE
Manufacturer
Sanofi-Aventis Deutschland GmbH
Country
Netherlands (NL)
ATC code
A10AE04
ATC class
Insulin glargine
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/00/134

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

433 interactions on record for insulin glargine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin glargine against other medicinesHow interaction checks work

Insulin glargine · interactions on record

433 records

  • 15 severe
  • 367 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin glargine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin glargine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Abasaglar, Abasaglar Kwikpen
  • Liechtenstein · Abasaglar, Abasaglar Kwikpen
  • Norway · Lantus, Lantus Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c64bfcd2-e633-4205-9850-8923e8d40dd5
GET /v1/drugs/c64bfcd2-e633-4205-9850-8923e8d40dd5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/lantus-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Insulin Glargine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp70696",
  "excipients": [
    "GLYCEROL 85 PER CENT (E 422)",
    "METACRESOL",
    "NATRIUMHYDROXIDE (E 524)",
    "POLYSORBAAT 20 (E 432)",
    "WATER VOOR INJECTIE",
    "ZINKDICHLORIDE 0-WATER",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "INSULINE GLARGINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2000/06/09",
  "procedure_number": "EMEA/H/C/000284",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/00/134",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about insulin glargine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console